Psychiatr. pro Praxi, 2006; 4: 168-170

Clinical benefit of pharmacogenetics in psychiatry

doc. MUDr. Ladislav Hosák Ph.D
Psychiatrická klinika LF UK a FN Hradec Králové

Pharmacogenetics deals with genetic aspects of pharmacotherapy especially related to therapeutic and adverse drug effects with a potential of their individual prediction. The number of published pharmacogenetic papers in psychiatry grows. In schizophrenia, nearly all studies published in the last century were concerned with clozapine, more recent publications also mention olanzapine, quetiapine, risperidone, ziprasidone and other preparations. Research into the 5-HT2A receptor gene looks promising with regard to prediction of treatment response to second generation antipsychotics. The results of studies on the 5-HTTLPR polymorphism of the gene for serotonin transporter are hopeful in the field of mood disorders. Pharmacogenetic findings have not yet been implemented into routine psychiatric practice, but this development can be expected in the future.

Keywords: pharmacogenetics, psychiatry, schizophrenia, mood disorders

Published: August 1, 2006  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Hosák L. Clinical benefit of pharmacogenetics in psychiatry. Psychiatr. praxi. 2006;7(4):168-170.
Download citation

References

  1. Bertolino A, Caforio G, Blasi G, De Candia M, Latorre V, Petruzzella V et al. Interaction of COMT Val108/158 Met Genotype and Olanzapine Treatment on Prefrontal Cortical Function in Patients With Schizophrenia. Am J Psychiatry 2004; 161: 1798-1805. Go to original source... Go to PubMed...
  2. Brudnak MA. Application of genomeceuticals to the molecular and immunological aspects of autism. Med Hypotheses 2001; 57: 186-191. Go to original source... Go to PubMed...
  3. Bruss M, Kostanian A, Bonisch H, Gothert M. The naturally occurring Arg219Leu variant of the human 5-HT1A receptor: impairment of signal transduction. Pharmacogenet Genomics 2005; 15: 257-264. Go to original source... Go to PubMed...
  4. Cacabelos R. Pharmacogenomics for the treatment of dementia. Ann Med 2002; 34: 357-379. Go to original source... Go to PubMed...
  5. Caspi A, Sugden K, Moffitt TE, Taylor A, Craig IW, Harrington H et al. Influence of life stress on depression: moderation by a polymorphism in the 5-HTT Gene. Science 2003; 301: 386-389. Go to original source... Go to PubMed...
  6. Gorwood P. Eating disorders, serotonin transporter polymorphisms and potential treatment response. Am J Pharmacogenomics 2004; 4: 9-17. Go to original source... Go to PubMed...
  7. Hong CJ, Chen TJ, Yu YW, Tsai SJ. Response to fluoxetine and serotonin 1A receptor (C1019G) polymorphism in Taiwan Chinese major depressive disorder. Pharmacogenomics J 2006; 6: 27-33. Go to original source... Go to PubMed...
  8. Horáček J, Libiger J, Höschl C, Borzová K, Hendrychová I. Clozapine-induced concordant agranulocytosis in monozygotic twins. Int J Psych Clin Practice 2001; 5: 71-73. Go to original source... Go to PubMed...
  9. Kenna GA, McGeary JE, Swift RM. Pharmacotherapy, pharmacogenomics, and the future of alcohol dependence treatment. Part 2. Am J Health Syst Pharm 2004; 61: 2380-2388. Go to original source... Go to PubMed...
  10. Lane HY, Chang YC, Chiu CC, Chen ML, Hsieh MH, Chang WH. Association of Risperidone Treatment Response With a Polymorphism in the 5-HT2A Receptor Gene. Am J Psychiatry 2002; 159: 1593-1595.
  11. Malhotra AK, Murphy GM, Kennedy JL. Pharmacogenetics of Psychotropic Drug Response. Am J Psychiatry 2004; 161: 780-796. Go to original source... Go to PubMed...
  12. Morley KI, Hall WD. Using pharmacogenetics and pharmacogenomics in the treatment of psychiatric disorders: some ethical and economic considerations. J Mol Medicine 2004; 82: 21-30. Go to original source... Go to PubMed...
  13. Murphy GM, Kremer C, Rodrigues HE, Schatzberg AF. Pharmacogenetics of antidepressant medication intolerance. Am J Psychiatry 2003; 160: 1830-1835. Go to original source... Go to PubMed...
  14. Pickar D, Rubinow K. Pharmacogenomics of psychiatric disorders. Trends Pharmacol Sci 2001; 22: 75-83. Go to original source... Go to PubMed...
  15. Pickar D, Rubinow K. Pharmacogenomics of schizophrenia. In: Briley M, Sulser F. (ed.) Molecular Genetics of Mental Disorders. Matin Dunitz 2001: 289-305.
  16. Rybakowski JK, Suwalska A, Czerski PM, Dmitrzak-Weglarz M, Leszczynska-Rodziewicz A, Hauser J. Prophylactic effect of lithium in bipolar affective illness may be related to serotonin transporter genotype. Pharmacol Rep 2005; 57: 124-127. Go to PubMed...
  17. Serretti A, Artioli P. The pharmacogenomics of selective serotonin reuptake inhibitors. Pharmacogenom J 2004; 4: 233-244. Go to original source... Go to PubMed...
  18. Snyderman R, Yoediono Z. Prospective care: a personalized, preventative approach to medicine. Pharmacogenomics 2006; 7: 5-9. Go to original source... Go to PubMed...
  19. Strober M. The future of treatment research in anorexia nervosa. Int J Eat Disord 2005; 37: S90-S94. Go to original source... Go to PubMed...
  20. Templeman LA, Reynolds GP, Arranz B, San L. Polymorphisms of the 5-HT2C receptor and leptin genes are associated with antipsychotic drug-induced weight gain in Caucasian subjects with a first-episode psychosis. Pharmacogenet Genomics 2005; 15: 195-200. Go to original source... Go to PubMed...
  21. Valevski A, Klein T, Gazit E, Meged S, Stein D, Elizur A et al. HLA-B38 and clozapine-induced agranulocytosis in Israeli Jewish schizophrenic patients. Eur J Immunogenet 1998; 25: 11-13. Go to original source... Go to PubMed...
  22. Weickert TW, Goldberg TE, Mishara A, Apud JA, Kolachana BS, Egan MF et al. Catechol-Omethyltransferase val108/158met genotype predicts working memory response to antipsychotic medications. Biol Psychiatry 2004; 56: 677-682. Go to original source... Go to PubMed...
  23. Yoshida K, Takahashi H, Higuchi H, Kamata M, Ito K, Sato K et al. Prediction of Antidepressant Response to Milnacipran by Norepinephrine Transporter Gene Polymorphism. Am J Psychiatry 2004; 161: 1575-1580. Go to original source... Go to PubMed...




Psychiatry for Practice

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.